# Cabozantinib in Men With Castration-Resistant Prostate Cancer

> **NCT01703065** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 9 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Castration-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage III Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT01703065
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06-18
- **Primary completion:** 2015-02-02
- **Final completion:** 2015-09-18
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015.
- **Last updated:** 2018-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703065, "Cabozantinib in Men With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01703065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*